Alshehabi Khadija M, Askandarani Sumayah, Alkhalifah Zainab A
Nephrology, Salmaniya Medical Complex, Manama, BHR.
Nephrology, King Fahad Specialist Hospital, Eastern Health Cluster, Dammam, SAU.
Cureus. 2022 May 21;14(5):e25183. doi: 10.7759/cureus.25183. eCollection 2022 May.
Rhabdomyolysis is a condition characterized by the destruction of the skeletal muscle and the release of its content into the circulation, and it can cause acute kidney injury (AKI). There are numerous causes for the development of this condition, and some of them are rare. Levetiracetam, an antiepileptic agent, has been speculated as a rare possibility for the development of rhabdomyolysis. In this report, we highlight a case of a 36-year-old gentleman with retinoblastoma since childhood, who was maintained on levetiracetam for two years for epilepsy. He was brought to our hospital with a history of generalized fatigue and unwitnessed seizure. Upon further investigations, he was found to have severe rhabdomyolysis and AKI that required renal replacement therapy. Levetiracetam was suspected as a culprit and therefore was discontinued with gradual improvement of renal function over a few months.
横纹肌溶解症是一种以骨骼肌破坏及其内容物释放进入循环系统为特征的病症,它可导致急性肾损伤(AKI)。导致这种病症的原因众多,其中一些较为罕见。左乙拉西坦,一种抗癫痫药物,被推测为横纹肌溶解症发生的一种罕见诱因。在本报告中,我们重点介绍了一名自童年起就患有视网膜母细胞瘤的36岁男性病例,他因癫痫服用左乙拉西坦两年。他因全身疲劳和不明原因的癫痫发作史被送往我院。经过进一步检查,发现他患有严重的横纹肌溶解症和急性肾损伤,需要进行肾脏替代治疗。怀疑左乙拉西坦是罪魁祸首,因此停用该药,随后肾功能在几个月内逐渐改善。